In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Nordisk A/S

https://www.novonordisk.com/

Latest From Novo Nordisk A/S

Novo Holdings Acquires BBI Group In Deal Worth Over $400M

To bolster its life sciences and diagnostics portfolios, Novo Holdings has made another major investment to acquire BBI Group.

M & A In Vitro Diagnostics

Roche’s Novel Ranibizumab Implant Among Myriad New Filings In EU

The European Medicines Agency has added 13 new drugs to its list of products that are under review for potential pan-EU marketing approval.

Drug Review Europe

Deal Watch: AbbVie To Try Caraway’s Lysosomal Function Approach To Parkinson’s

Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.

Deals Business Strategies

Asia Deal Watch: Heartseed Licenses Lead Cell Therapy Candidate To Novo Nordisk

Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Carbometrics
    • Corvidia Therapeutics
    • Neose Technologies, Inc.
    • Novo Holdings A/S
    • Novo Nordisk Pharmaceuticals, Inc.
    • Pharmaero Aps
    • Xellia Pharmaceuticals ApS
    • Ziylo Ltd
UsernamePublicRestriction

Register